Takeda buys coeliac drug licence from COUR PharmaceuticalsTakeda has bought a licence for a coeliac disease drug from COUR Pharmaceuticals, after the US biotech announced Share XTakeda buys coeliac drug licence from COUR Pharmaceuticalshttps://pharmaphorum.com/news/takeda-buys-coeliac-drug-licence-from-cour-pharmaceuticals/
AZ sells rights to gastro drug Losec to Cheplapharm in $309m dealAstraZeneca has agreed to sell most global commercial rights to its gastro drug Losec (omeprazole) and associated brands Share XAZ sells rights to gastro drug Losec to Cheplapharm in $309m dealhttps://pharmaphorum.com/news/az-sells-rights-to-gastro-drug-losec-to-cheplapharm/
Multiple pharmas pull ranitidine stomach drugs amid growing cancer scareSupplies of the heartburn drug ranitidine have been recalled globally following a cancer scare involving multiple pharma companies, Share XMultiple pharmas pull ranitidine stomach drugs amid growing cancer scarehttps://pharmaphorum.com/news/multiple-pharmas-pull-ranitidine-stomach-drugs-amid-growing-cancer-scare/
AZ takes control of Ironwood’s IBS drug in ChinaAstraZeneca has amended a collaboration agreement with Ironwood Pharmaceuticals, gaining sole responsibility for developing, manufacturing and marketing an Share XAZ takes control of Ironwood’s IBS drug in Chinahttps://pharmaphorum.com/news/az-takes-control-of-ironwoods-ibs-drug-in-china/
J&J gets Stelara okay in Europe for ulcerative colitisJohnson & Johnson’s inflammatory disease drug Stelara has been approved in Europe for ulcerative colitis (UC), a new Share XJ&J gets Stelara okay in Europe for ulcerative colitishttps://pharmaphorum.com/news/jj-gets-stelara-okay-in-europe-for-ulcerative-colitis/
Lilly moves Crohn’s drug into phase 3, faces safety setback in JapanEli Lilly has had a mixed few days, posting promising trial results for mid-stage Crohn’s disease drug mirikizumab, Share XLilly moves Crohn’s drug into phase 3, faces safety setback in Japanhttps://pharmaphorum.com/news/lilly-moves-crohns-drug-mirikizumab/
EU regulators slap safety restriction on Pfizer’s XeljanzEuropean safety regulators have placed restrictions on Pfizer’s Xeljanz, saying it should not be used in the higher Share XEU regulators slap safety restriction on Pfizer’s Xeljanzhttps://pharmaphorum.com/news/eu-regulators-slap-safety-restriction-on-pfizers-xeljanz/
J&J unveils top pipeline prospects, with main focus on cancerJohnson & Johnson has shone the spotlight on the most promising drugs in its pipeline, saying it plans Share XJ&J unveils top pipeline prospects, with main focus on cancerhttps://pharmaphorum.com/news/jj-unveils-top-pipeline-prospects-cancer/
Takeda’s Entyvio outperforms AbbVie’s Humira in GI trialTakeda has announced results from its gastro drug Entyvio, showing that it largely outperformed the industry standard – Share XTakeda’s Entyvio outperforms AbbVie’s Humira in GI trialhttps://pharmaphorum.com/news/takedas-entyvio-outperforms-abbvies-humira-in-gi-trial/
